Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,425 | -6,528 | -30,150 | -25,818 | -19,756 |
| Depreciation Amortization | 2 | 1 | 5 | 4 | 2 |
| Other Working Capital | 5,334 | 2,287 | 5,164 | 2,742 | 1,930 |
| Other Operating Activity | 2,856 | 569 | 3,324 | 4,607 | 3,923 |
| Operating Cash Flow | $-6,233 | $-3,671 | $-21,657 | $-18,465 | $-13,901 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -3 | -4 | -2 |
| Investing Cash Flow | $N/A | $N/A | $-3 | $-4 | $-2 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 943 | 786 | 786 |
| Debt Repayment | -2,156 | -2,155 | -4,035 | -2,762 | -90 |
| Common Stock Issued | 5,692 | 2,550 | 8,122 | 8,122 | 8,122 |
| Other Financing Activity | 0 | 0 | 1,171 | 1,171 | 0 |
| Financing Cash Flow | $3,536 | $395 | $6,201 | $7,317 | $8,818 |
| Beginning Cash Position | 4,595 | 4,595 | 20,054 | 20,054 | 20,054 |
| End Cash Position | 1,898 | 1,319 | 4,595 | 8,902 | 14,969 |
| Net Cash Flow | $-2,697 | $-3,276 | $-15,459 | $-11,152 | $-5,085 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,233 | -3,671 | -21,657 | -18,465 | -13,901 |
| Capital Expenditure | N/A | N/A | -3 | -4 | -2 |
| Free Cash Flow | -6,233 | -3,671 | -21,660 | -18,469 | -13,903 |